Hims & Hers Health, Inc.

Hims & Hers runs a direct-to-consumer telehealth pharmacy — GLP-1s, hair, skin, mental health, testosterone — that turned into a growth stock on the back of compounded weight-loss peptides. That growth engine now sits in the crosshairs of a July 23-24 FDA advisory committee.

The setup, plainly:

• Growth has already stepped down: Q1 revenue grew just 3.8% YoY vs 28-73% in the prior four quarters, so the deceleration is visible even before the FDA rules on whether the compounded peptides can continue at all.
• The peptide vertical is the whole optionality: Boots UK described its Wegovy pill launch as one of the busiest customer-consultation days ever, and Hims began retatrutide pre-orders on June 12 — the bull case Needham has flagged ('not factored into HIMS valuation at all yet') is now a binary on the FDA meeting.
• The balance sheet is being stretched to run the play: a fresh $400M JPMorgan receivables facility plus a 0.00% convertible note tell you management is funding the ramp with tomorrow's dilution rather than today's cash — debt-to-equity is now 2.5x.
• Insiders are selling into the catalyst: CFO Oluyemi Okupe, CTO Mohamed Elshenawy, president Michael Chi, and several other officers cleared over $3M combined in the last month — a cluster of sales into a binary regulatory event is not the vote of confidence bulls want.

The two-day advisory committee is the entire near-term trade: a favorable read (peptides stay legally reachable via compounding) and the stock retests $60; a hard skeptical vote (staff docs already lean that way) and it revisits the March lows quickly. Q2 earnings on August 10 is the second checkpoint but it plays out under whatever FDA verdict landed.